Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema

被引:46
作者
Gao, Shanshan [1 ]
Tian, Baocheng [1 ]
Han, Jingtian [1 ]
Zhang, Jing [1 ]
Shi, Yanan [1 ]
Lv, Qingzhi [1 ]
Li, Keke [1 ]
机构
[1] Binzhou Med Univ, Sch Pharm, 346 Guanhai Rd, Yantai 264003, Peoples R China
基金
中国国家自然科学基金;
关键词
lornoxicam; nanostructured lipid carriers; cell penetrating peptides; transdermal drug delivery; anti-inflammatory effect; CELL-PENETRATING PEPTIDES; DRUG-DELIVERY; IN-VITRO; PHYSICAL-CHARACTERIZATION; CHITOSAN CHLORIDE; NITRIC-OXIDE; EX-VIVO; SKIN; NANOPARTICLES; PERMEATION;
D O I
10.2147/IJN.S205295
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: Nanostructured lipid carriers (NLCs) are emerging as attractive drug carriers in transdermal drug delivery. The surface modification of NLCs with cell-penetrating peptides (CPPs) can enhance the skin permeation of drugs. Purpose: The objective of the current study was to evaluate the ability of the cell-penetrating peptide (CPP) polyarginine to translocate NLCs loaded with lornoxicam (LN) into the skin layers and to evaluate its anti-inflammatory effect. Methods: The NLCs were prepared using an emulsion evaporation and low temperature solidification technique using glyceryl monostearates, triglycerides, DOGS-NTA-Ni lipids and surfactants, and then six histidine-tagged polyarginine containing 11 arginine (R11) peptides was modified on the surface of NLCs. Results: The developed NLCs formulated with LN and R11 (LN-NLC-R11) were incorporated into 2% HPMC gels. NLCs were prepared with a particle size of (121.81 +/- 3.61)-(145.72 +/- 4.78) nm, and the zeta potential decreased from (-30.30 +/- 2.07) to (-14.66 +/- 0.74) mV after the modification of R11 peptides. The encapsulation efficiency and drug loading were (74.61 +/- 1.13) % and (7.92 +/- 0.33) %, respectively, regardless of the surface modification. Cellular uptake assays using HaCaT cells suggested that the NLC modified with R11 (0.02%, w/w) significantly enhanced the cell internalization of nanoparticles relative to unmodified NLCs (P<0.05 or P<0.01). An in vitro skin permeation study showed better permeation-enhancing ability of R11 (0.02%, w/w) than that of other content (0.01% or 0.04%). In carrageenan-induced rat paw edema models, LN-NLC-R11 gels inhibited rat paw edema and the production of inflammatory cytokines compared with LN-NLC gels and LN gels (P<0.01). Conclusion: In our investigation, it was strongly demonstrated that the surface modification of NLC with R11 enhanced the translocation of LN across the skin, thereby alleviating inflammation.
引用
收藏
页码:6135 / 6150
页数:16
相关论文
共 57 条
[1]   Lipid nanocapsules for dermal application: A comparative study of lipid-based versus polymer-based nanocarriers [J].
Abdel-Mottaleb, Mona M. A. ;
Neumann, Dirk ;
Lamprecht, Alf .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2011, 79 (01) :36-42
[2]   Evaluation of Skin Permeation and Analgesic Activity Effects of Carbopol Lornoxicam Topical Gels Containing Penetration Enhancer [J].
Al-Suwayeh, Saleh A. ;
Taha, Ehab I. ;
Al-Qahtani, Fahad M. ;
Ahmed, Mahrous O. ;
Badran, Mohamed M. .
SCIENTIFIC WORLD JOURNAL, 2014,
[3]   Topical liquid crystalline gel containing lornoxicam/cyclodextrin complex [J].
Ammar, H. O. ;
Ghorab, M. ;
Mahmoud, A. A. ;
Makram, T. S. ;
Noshi, S. H. .
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, 2012, 73 (1-4) :161-175
[4]   Role of nitric oxide in the physiopathology of pain [J].
Anbar, M ;
Gratt, BM .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 14 (04) :225-254
[5]   Development, characterization, and skin delivery studies of related ultradeformable vesicles: transfersomes, ethosomes, and transethosomes [J].
Ascenso, Andreia ;
Raposo, Sara ;
Batista, Catia ;
Cardoso, Pedro ;
Mendes, Tiago ;
Praca, Fabiola Garcia ;
Lopes Badra Bentley, Maria Vitoria ;
Simoes, Sandra .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10 :5837-5851
[6]   Influence of microneedle shape on the transport of a fluorescent dye into human skin in vivo [J].
Bal, Suzanne M. ;
Kruithof, Annelieke C. ;
Zwier, Raphael ;
Dietz, Ekkehart ;
Bouwstra, Joke A. ;
Lademann, Juergen ;
Meinke, Martina C. .
JOURNAL OF CONTROLLED RELEASE, 2010, 147 (02) :218-224
[7]   Lornoxicam - A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions [J].
Balfour, JA ;
Fitton, A ;
Barradell, LB .
DRUGS, 1996, 51 (04) :639-657
[8]  
BARRY B W, 1987, Journal of Controlled Release, V6, P85, DOI 10.1016/0168-3659(87)90066-6
[9]   The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro [J].
Berg, J ;
Fellier, H ;
Christoph, T ;
Grarup, J ;
Stimmeder, D .
INFLAMMATION RESEARCH, 1999, 48 (07) :369-379
[10]   A study on ethosomes as mode for transdermal delivery of an antidiabetic drug [J].
Bodade, Siddhodhan S. ;
Shaikh, Karimunnisa Sameer ;
Kamble, Meghana S. ;
Chaudhari, Praveen D. .
DRUG DELIVERY, 2013, 20 (01) :40-46